Human papillomavirus type 16 E7-specific CD8+ T lymphocyte (HPV16 E7-specific CD8+ T cell)

Human papillomavirus type 16 (HPV16) E7-specific CD8+ T cells are specialized cytotoxic lymphocytes that recognize and eliminate cells expressing the E7 oncoprotein, a primary driver of HPV-mediated malignancy (Draper et al., 2015, PMID: 25833271). The E7 protein promotes oncogenesis by binding and degrading the retinoblastoma (Rb) tumor suppressor protein, leading to the loss of cell cycle control and genomic instability (Stevanović et al., 2017, PMID: 28373504). These T cells identify specific E7-derived peptides, most notably the HLA-A*02:01-restricted E7 11-20 epitope, when presented by Major Histocompatibility Complex (MHC) class I molecules on the surface of infected or cancerous cells. Therapeutic interventions, such as adoptive T-cell receptor (TCR) engineered T-cell therapies (e.g., KITE-439) and therapeutic vaccines (e.g., ISA101), are designed to expand or generate this T cell population to achieve durable tumor regression in patients with cervical, oropharyngeal, and anal cancers (National Cancer Institute, 2023). Because E7 is a viral protein not expressed in healthy human tissues, these T cells offer a highly specific therapeutic approach with a low risk of off-target toxicity. Their efficacy can be further enhanced by combination with immune checkpoint inhibitors, which prevent T cell exhaustion within the immunosuppressive tumor microenvironment.

Other names

HPV16 E7-reactive CD8+ T cellsHPV16 E7-specific cytotoxic T lymphocytesE7-CTLsHPV16 E7-specific T cells

Recognition of HPV16 E7-derived peptides presented by MHC class I molecules on the surface of tumor cells, leading to the release of cytotoxic granules (perforin/granzymes) and pro-inflammatory cytokines like IFN-gamma to induce apoptosis.